ESC Professional Premium Access

Novel medication strategies in atrial fibrillation

Event: ESC Congress 2022
Topic: Treatment
Session type: Moderated ePosters
Date: 29 August 2022
Time: 14:15 - 15:00

Congress Session

6 presentations in this session

Dronedarone as early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET4 criteria

Speaker: Professor J. Piccini (Durham, US)
Thumbnail

Amiodarone and Lung Toxicity in a real-life contemporary population

Speaker: Doctor G. Tsaban (Beer Sheva, IL)
Thumbnail

Chronic amiodarone therapy and mortality among atrial fibrillation patients; insights from a real-life contemporary population

Speaker: Doctor G. Tsaban (Beer Sheva, IL)
Thumbnail

Alleviation of AF related symptoms following acute conversion of recent-onset, symptomatic atrial fibrillation to sinus rhythm with flecainide acetate oral inhalation solution

Speaker: Professor J. Camm (London, GB)
Thumbnail

Amiodarone therapy and risk of primary lung cancer; insights from a real-life contemporary population study

Speaker: Doctor G. Tsaban (Beer Sheva, IL)
Thumbnail

Predictors of successful cardioversion of recent-onset atrial fibrillation to sinus rhythm with orally inhaled flecainide

Speaker: Doctor H. Crijns (Maastricht, NL)
Thumbnail

6 speakers from this session

Professor Jonathan Piccini

Duke University Medical Center, Durham (United States of America)
4 presentations
0 follower

Doctor Gal Tsaban

Soroka University Medical Center, Beer Sheva (Israel)
0 follower

Doctor Gal Tsaban

Soroka University Medical Center, Beer Sheva (Israel)
0 follower

Professor John Camm

St George's University of London, London (United Kingdom of Great Britain & Northern Ireland)
56 presentations
1 follower

Doctor Gal Tsaban

Soroka University Medical Center, Beer Sheva (Israel)
0 follower

Doctor Harry Crijns

Maastricht University Medical Centre (MUMC), Maastricht (Netherlands (The))
17 presentations
0 follower

This platform is supported by

logo Novo Nordisk